Home Cart Sign in  
Chemical Structure| 164301-51-3 Chemical Structure| 164301-51-3

Structure of Semapimod 4HCl
CAS No.: 164301-51-3

Chemical Structure| 164301-51-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Semapimod is an effective pro-inflammatory cytokine inhibitor that inhibits the production of TNF-α, IL-1β, and IL-6, showing activity against macrophage p38 MAPK and TLR4 signaling, suitable for research on inflammation and autoimmune diseases.

Synonyms: CNI-1493; CPSI-2364 tetrahydrochloride; Semapimod tetrahydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Semapimod 4HCl

CAS No. :164301-51-3
Formula : C34H56Cl4N18O2
M.W : 890.74
SMILES Code : O=C(NC1=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C1)CCCCCCCCC(NC2=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C2)=O.[H]Cl.[H]Cl.[H]Cl.[H]Cl
Synonyms :
CNI-1493; CPSI-2364 tetrahydrochloride; Semapimod tetrahydrochloride
MDL No. :MFCD23160046

Safety of Semapimod 4HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H315-H319-H332-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of Semapimod 4HCl

MAPK
pyroptosis
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW264.7 cells 1 µM 1 hour CNI-1493 suppressed TNF translation through both 5' and 3' untranslated regions of TNF mRNA Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3967-71
Human peripheral blood mononuclear cells (PBMCs) 1 µM 1 hour CNI-1493 inhibited LPS-stimulated TNF protein synthesis Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3967-71
Rat IEC-6 intestinal epithelioid cells 0.3 µM (IC50) 15 minutes Inhibits TLR ligand-induced activation of p38 MAPK, NF-kB, and COX-2, but not activation by IL-1β or stresses. J Immunol. 2016 Jun 15;196(12):5130-7
SH-SY5Y neuroblastoma cells 2.5 µM 15 minutes To assess the effect of CNI-1493 on Aβ oligomer toxicity, results showed that CNI-1493 pretreatment completely abolished the toxicity of Aβ oligomers J Exp Med. 2008 Jul 7;205(7):1593-9
HEK293 cells 10 µM 2 hours Investigated the effect of Semapimod on gp96-TLR4 complexes, showing no effect on co-immunoprecipitation of gp96 and TLR4. J Immunol. 2016 Jun 15;196(12):5130-7
SW480 enterocytes 2 µM 3 hours Semapimod caused accumulation of TLR4 and TLR9 in perinuclear space, consistent with ER retention. J Immunol. 2016 Jun 15;196(12):5130-7

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Hepatoma model Intraperitoneal injection 1 mg/kg/day Once daily for 14 days CNI-1493 markedly protected animals from IL-2 systemic toxicities whereas not affecting tumor response to IL-2 therapy. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4561-6
Transgenic TgCRND8 mice Alzheimer's disease model Intraperitoneal injection 200 μg (8 mg/kg) Twice a week for 8 weeks To evaluate the effect of CNI-1493 on Aβ plaque formation and cognitive function, results showed that CNI-1493 significantly reduced Aβ plaque deposition and improved cognitive function in mice J Exp Med. 2008 Jul 7;205(7):1593-9
Mice Oxygen-induced retinopathy (OIR) model Intraperitoneal injection 5 mg/kg Once daily from P12 to P17 Inhibition of TNF-α significantly improves vascular recovery within ischemic tissue and reduces pathological neovascularization in OIR. Am J Pathol. 2005 Feb;166(2):637-44
DA rats Collagen-induced arthritis (CIA) Intraperitoneal injection 5 mg/kg/day Once daily until the end of the experiment To investigate the protective effect of CNI-1493 on joint destruction in CIA rats. Results showed that CNI-1493 significantly reduced clinical signs of arthritis and cartilage destruction, and serum COMP levels were significantly lower in the CNI-1493 treated group. Ann Rheum Dis. 2005 Mar;64(3):494-6
Adult male Lewis rats Endotoxin-induced shock model Intravenous and intracerebroventricular (i.c.v.) Intravenous: 100 µg/kg to 500 µg/kg; i.c.v.: 0.1 ng/kg to 1000 ng/kg Single dose, endotoxin administered 60 minutes later To investigate the mechanism by which CNI-1493 inhibits endotoxin-induced TNF release and shock via the cholinergic antiinflammatory pathway. Results showed that i.c.v. administration was significantly more effective than intravenous dosing and required intact vagus nerve signaling. J Exp Med. 2002 Mar 18;195(6):781-8

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.12mL

0.22mL

0.11mL

5.61mL

1.12mL

0.56mL

11.23mL

2.25mL

1.12mL

 

Historical Records

Categories